Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first‐line treatment in adults with transplant‐ineligible multiple myeloma: a network meta‐analysis

BACKGROUND: Multiple myeloma is a bone marrow‐based hematological malignancy accounting for approximately two per cent of cancers. First‐line treatment for transplant‐ineligible individuals consists of multiple drug combinations of bortezomib (V), lenalidomide (R), or thalidomide (T). However, acces...

Full description

Saved in:
Bibliographic Details
Published in:Cochrane Database Syst Rev
Main Authors: Piechotta, Vanessa, Jakob, Tina, Langer, Peter, Monsef, Ina, Scheid, Christof, Estcourt, Lise J, Ocheni, Sunday, Theurich, Sebastian, Kuhr, Kathrin, Scheckel, Benjamin, Adams, Anne, Skoetz, Nicole
Format: Artigo
Language:Inglês
Published: John Wiley & Sons, Ltd 2019
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6876545/
https://ncbi.nlm.nih.gov/pubmed/31765002
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD013487
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items